Pancreatic Cancer
If it’s your first time on this website, please read the disclaimer section.
Oct 12 – Oct 19, 2026
Clinical Efficacy of Tislelizumab Plus Gemcitabine-Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer and Chemoresistance Analysis: A Prospective Pilot Study.
ANN SURG ONCOL · Q1 JOURNAL - RANK #39/312
This prospective pilot study evaluated the clinical feasibility of neoadjuvant tislelizumab plus gemcitabine-nab-paclitaxel in 30 patients with borderline resectable pancreatic cancer, with primary endpoints of R0 resection rate and treatment-related adverse events. Results showed 80.0% (24/30) completed neoadjuvant therapy and underwent resection, with R0 resection achieved in 80.0% (24/30) of all patients and 100% (24/24) of resected patients; 12-month OS and RFS rates were 87.5% and 82.8%, respectively, with median RFS of 28 months. Most TRAEs were grade I-II with no serious events, and exploratory proteomics/machine learning identified NT5DC2, FAM3D, CXCL5, and TMT1B as candidate resistance biomarkers. The authors conclude that this neoadjuvant regimen is promising for improving resection rates in BRPC with a favorable safety profile, warranting validation in larger-scale studies.
10.1245/s10434-026-20711-3
Sep 28 – Oct 05, 2026
Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomized phase 2b trial.
NAT MED · Q1 JOURNAL - RANK #1/195TOP-TIER
This randomized phase 2b trial evaluated intravenous hyaluronidase-expressing oncolytic adenovirus VCN-01 plus gemcitabine/nab-paclitaxel (GnP) versus GnP alone as first-line therapy in metastatic pancreatic ductal adenocarcinoma. In the intent-to-treat population (VCN-01+GnP n=53; GnP n=48), median overall survival was 10.6 vs 8.6 months (HR=0.69, 95% CI 0.42-1.12, P=0.196) and progression-free survival was 5.6 vs 4.6 months (HR=0.63, P=0.046). In the full analysis set (n=48 per group), median OS was 10.8 vs 8.6 months (HR=0.57, P=0.055) and PFS was 7.0 vs 4.6 months (HR=0.55, P=0.011), with the primary OS endpoint met. The authors conclude that VCN-01 combined with GnP shows promise and warrants a blinded phase 3 trial.
10.1038/s41591-026-04705-y
Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study with single-cell correlatives.
NAT COMMUN · Q1 JOURNAL - RANK #10/135TOP-TIER
This open-label, single-arm phase 2 trial evaluated motixafortide, cemiplimab, gemcitabine, and nab-paclitaxel (MCGN) in 11 treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma. The primary endpoint of objective response rate was 64% partial response and 55% confirmed partial response, with median progression-free survival of 9.7 months and overall survival of 10.1 months. Exploratory single-nucleus RNA-sequencing showed reduced tumor heterogeneity and enrichment of CXCL12+ cancer-associated fibroblasts in responders. The authors conclude MCGN is promising and a randomized phase 2 trial comparing MCGN to GN is ongoing.
10.1038/s41467-026-76559-4
Sep 21 – Sep 28, 2026
Clinical and Proteomic Biomarkers of Trifluridine/Tipiracil in Fluoropyrimidine-Refractory Advanced Pancreatic Adenocarcinoma: A Single-Arm Phase II Trial.
JCO PRECIS ONCOL · Q1 JOURNAL - RANK #57/326
This single-arm phase II trial evaluated trifluridine/tipiracil (FTD/TPI) in 28 patients with fluoropyrimidine-refractory advanced pancreatic adenocarcinoma, administering the drug on days 1-5 and 8-12 of 28-day cycles. The primary endpoint, 16-week progression-free survival (PFS) rate, was 35.7% (95% CI, 17.8-53.2), with median PFS of 3.3 months and median overall survival of 4.6 months. Grade 3+ toxicities included neutropenia (32.1%) and anemia (14.3%). The authors conclude FTD/TPI shows potential efficacy and acceptable safety in this population, though randomized trials are needed for validation.
10.1200/PO-26-00323
Sep 14 – Sep 21, 2026
Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer.
CANCER CELL · Q1 JOURNAL - RANK #5/326TOP-TIER
This phase 1/2 trial evaluated HRS-4642, a selective KRAS G12D inhibitor, combined with adebrelimab (PD-L1 blockade) in 48 pretreated patients with metastatic KRAS G12D-mutant pancreatic ductal adenocarcinoma. Dose escalation established the recommended phase 2 dose (RP2D) with no dose-limiting toxicities or treatment-related deaths; hypercholesterolemia and anemia were the most common adverse events. In the RP2D cohort (n=37), the objective response rate was 43.2%, disease control rate was 81.1%, median duration of response 6.9 months, median progression-free survival 5.7 months, and median overall survival 11.5 months. The authors conclude this chemotherapy-free regimen is tolerable with encouraging antitumor activity, warranting further study.
10.1016/j.ccell.2026.08.012
Triplet chemotherapy with Gemcitabine, Nab-paclitaxel, and S-1 achieves high response and conversion rates in advanced pancreatic cancer: A multicenter phase II study (GeNeS1S trial).
EUR J CANCER · Q1 JOURNAL - RANK #45/326
This multicenter, single-arm phase II trial evaluated triplet chemotherapy with gemcitabine, nab-paclitaxel, and S-1 in 30 patients with previously untreated locally advanced, recurrent, or metastatic pancreatic cancer. Treatment consisted of gemcitabine (600 mg/m²) and nab-paclitaxel (90 mg/m²) on days 1 and 8 plus oral S-1 (50/70/80 mg/day) on days 1-14 of a 3-week cycle. The primary endpoint of objective response rate was met at 63.3% (95% CI, 45.5-78.2), with median progression-free survival of 9.0 months and overall survival of 15.0 months; grade ≥3 adverse events were mainly hematologic. The authors conclude that the triplet regimen demonstrates high antitumor activity and encouraging conversion to resection, supporting further evaluation in borderline resectable or locally advanced disease.
10.1016/j.ejca.2026.117034
Short-term versus long-course neoadjuvant chemotherapy for resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results from the second randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial.
ECLINICALMEDICINE · Q1 JOURNAL - RANK #11/332
This second randomization of the PACT-21 CASSANDRA phase 3 trial compared long (6 months) versus short (4 months preoperative plus 2 months postoperative) neoadjuvant chemotherapy in 165 patients with resectable or borderline resectable pancreatic ductal adenocarcinoma. Patients initially received either PAXG or mFOLFIRINOX, and those without progression after 4 months were randomized to continue chemotherapy either before or after surgery. No significant difference in event-free survival was observed (HR 0.98, 95% CI 0.68-1.41, p=0.90), while longer chemotherapy improved CA19-9 response (97% vs 84%, p=0.02), pathological complete response (5% vs 0%, p=0.05), and N0 resection rate (45% vs 27%, p=0.01). The authors concluded that long and short preoperative chemotherapy yield similar EFS in this population, and future research should focus on more effective regimens and optimal postoperative therapy.
10.1016/j.eclinm.2026.104190
Sep 07 – Sep 14, 2026
Safety and efficacy of cisplatin and nab-paclitaxel pressurised intraperitoneal aerosol chemotherapy (PIPAC) in patients with peritoneal carcinomatosis: Nab-PIPAC phase 1b study.
EBIOMEDICINE · Q1 JOURNAL - RANK #13/195TOP-TIER
This phase 1b trial evaluated the safety, tolerability, and pharmacokinetics of combined cisplatin and nab-paclitaxel administered via pressurized intraperitoneal aerosol chemotherapy (PIPAC) in 22 patients with peritoneal carcinomatosis, using a 3+3 dose escalation design for nab-paclitaxel (7.5–70 mg/m²) with fixed cisplatin (10.5 mg/m²). Of 18 patients who received at least one PIPAC, 45 procedures were performed, with 67% completing three cycles; no dose-limiting toxicities occurred, and the most common adverse event was abdominal pain. Median progression-free survival was 3.5 months and median overall survival was 9.4 months, with five gastrointestinal cancer patients surviving beyond one year; pharmacokinetic analysis showed linearity between nab-paclitaxel dose and AUC (R²=0.90). The authors concluded that the combination was safe and well tolerated, warranting further investigation.
10.1016/j.ebiom.2026.106477
Aug 31 – Sep 07, 2026
Synthetic long peptide and DNA personalized cancer vaccines induce robust neoantigen-specific T cell responses in pancreatic cancer.
SCI ADV · Q1 JOURNAL - RANK #12/135TOP-TIER
This study reports two phase 1 clinical trials (NCT03956056 and NCT03122106) evaluating synthetic long peptide (SLP) and DNA personalized cancer vaccines (PCVs) in pancreatic ductal adenocarcinoma (PDAC) patients following surgical resection and adjuvant chemotherapy. Tumor/normal whole-exome and RNA sequencing with pVACtools identified and prioritized candidate neoantigens for vaccine design. Vaccines were well tolerated with no grade ≥3 adverse events, and neoantigen-specific T cell responses were confirmed via interferon-γ ELISPOT, intracellular cytokine staining, and TCR clonotype transduction. Compared to a propensity-matched cohort, PCV patients showed a non-significant trend toward prolonged median overall survival (4.4 vs 3.5 years, log-rank p = 0.23), indicating PCVs are safe, feasible, and immunogenic.
10.1126/sciadv.aei1190
L-Glutamine in combination with first-line gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: an open-label, single-arm, phase 1 GlutaPanc trial.
NAT CANCER · Q1 JOURNAL - RANK #11/326TOP-TIER
This open-label, single-arm, phase 1 trial evaluated the safety and preliminary efficacy of adding oral L-glutamine to standard gemcitabine and nab-paclitaxel (GA) in 16 treatment-naive patients with advanced pancreatic ductal adenocarcinoma. Using an adaptive Bayesian design, the primary endpoint was met, with the recommended phase 2 dose established at the maximum doses of both agents. The grade ≥3 treatment-related adverse event rate was 66.7%, primarily attributed to GA. Tumor shrinkage occurred in 94% of subjects, with a best overall response rate of 44% (including 12.5% complete responses), median progression-free survival of 8.5 months (95% CI 6-not reached), and median overall survival of 22 months (95% CI 11-not reached), suggesting improved efficacy compared to historical GA alone.
10.1038/s43018-026-01225-z